Related Experiment Video
Updated: Dec 14, 2025
04:24
A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
Published on: April 19, 2019
12.1K
[Cardiovascular prevention in the elderly: limitations and opportunities]
Maurizio Giuseppe Abrignani1, Alessandro Aiello2, Furio Colivicchi2
1U.O.C. Cardiologia, P.O. S. Antonio Abate di Trapani, ASP Trapani.
Giornale Italiano Di Cardiologia (2006)
|July 21, 2020
Summary
As populations age, the risk of multiple chronic illnesses, including cardiovascular disease, increases. Cardiovascular prevention strategies in the elderly require tailored approaches due to frailty and comorbidities.
Area of Science:
- Gerontology
- Cardiology
- Public Health
Background:
- Global populations are aging, leading to increased prevalence of chronic illnesses and multimorbidity.
- Aging is a primary risk factor for cardiovascular disease (CVD) and associated comorbidities.
- Elderly individuals, especially those with comorbidities, are underrepresented in clinical trials for CVD prevention.
Purpose of the Study:
- To review the complex relationship between aging and cardiovascular disease.
- To highlight challenges in cardiovascular prevention for the elderly population.
- To discuss uncertainties regarding treatment intensity and targets in older adults.
Main Methods:
- Literature review focusing on aging, multimorbidity, and cardiovascular disease.
- Analysis of cardiovascular risk factors in the context of aging.
- Examination of clinical trial representation and treatment considerations for elderly patients.
Main Results:
- Aging significantly increases the risk and incidence of cardiovascular disease.
- Multimorbidity and age-related homeostatic dysregulation are key challenges in elderly health.
- Current prevention trials inadequately represent frail elderly individuals with comorbidities.
Conclusions:
- Cardiovascular prevention in the elderly necessitates specialized strategies considering age-related changes and comorbidities.
- Further research is needed to optimize therapeutic targets and treatment protocols for older adults.
- Addressing the underrepresentation of the elderly in clinical trials is crucial for effective CVD prevention.
More Related Videos
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
12.9K
07:21Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
1.2K
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
515
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
515
01:15Drug Dosing: Geriatric Patients
149
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
149
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
125
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
125
01:26Atherosclerosis III: Management
255
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
255
01:29Cardiomyopathy V: Interprofessional Care
201
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
201
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
118
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
118